FDA Brief

Company record

Breckenridge Pharmaceutical, Inc.

0 FDA warning letters since 2023 and 5 recalls in the last 12 months.

Get an email the day FDA posts anything new about Breckenridge Pharmaceutical, Inc..

Recalls

ReportedClassFirmProduct and reason
Jun 17 Class II Breckenridge Pharmaceutical, Inc.
Drug
Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by…
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Jun 17 Class II Breckenridge Pharmaceutical, Inc.
Drug
Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berke…
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
May 13 Class II Breckenridge Pharmaceutical, Inc.
Drug
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, …
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Dec 10, 2025 Class II Breckenridge Pharmaceutical, Inc.
Drug
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkel…
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Dec 10, 2025 Class II Breckenridge Pharmaceutical, Inc.
Drug
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC…
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit